# HPV & HBV vaccination

Source: https://onco.cc/technologies/hpv-vaccine/  
OnCo record `hpv-vaccine` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vaccines that prevent the viral infections behind cervical, throat, anal, and liver cancers. The most effective anti-cancer intervention ever created.

## Summary

HPV and HBV vaccines are virus-like particle vaccines that induce neutralising antibodies, preventing the persistent oncogenic infections that cause cervical, throat, anal, and liver cancers. Gardasil 9 prevents around 90% of cervical cancers, and Scotland and Sweden report near-zero cervical cancer in fully vaccinated cohorts. The WHO targets cervical cancer elimination through its 90-70-90 goals for vaccination, screening, and treatment, and HBV vaccination has reduced liver cancer incidence in Taiwan and elsewhere. Single-dose HPV schedules expand coverage where multi-dose programmes are hard to deliver, and the vaccines are cheap at scale. Coverage gaps and vaccine hesitancy are the remaining obstacles. The simple version is that these vaccines prevent cancer outright, making them the most effective anti-cancer intervention ever created.

## Fields

- Kind: Technology
- Status: standard-of-care
- Last checked: 2026-09-04
- Principle: Virus-like particle vaccines induce neutralising antibodies preventing persistent oncogenic infection.
- Strengths: Prevents cancer outright; Cheap at scale
- Limitations: Coverage gaps, vaccine hesitancy

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/HPV_vaccine
- Wikipedia: https://en.wikipedia.org/wiki/HPV_vaccine

## Connected records

- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/), [Paths to cures: interception, eradication, control](https://onco.cc/roadmaps/cure-paths/)
- cancers: [Anal cancer (squamous cell carcinoma)](https://onco.cc/cancers/anal/), [Anal high-grade squamous intraepithelial lesions (precursor)](https://onco.cc/cancers/anal-hsil-precursor/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Early cervical cancer and fertility-sparing surgery](https://onco.cc/cancers/early-cervical-cancer/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HPV-associated vulvar squamous cell carcinoma](https://onco.cc/cancers/hpv-associated-vulvar-cancer/), [HPV-positive oropharyngeal cancer](https://onco.cc/cancers/hpv-positive-oropharyngeal-cancer/), [Localised penile cancer (organ-confined, node-negative)](https://onco.cc/cancers/localised-penile-cancer/), [Oropharyngeal cancer (tonsil and base of tongue)](https://onco.cc/cancers/oropharyngeal-cancer/), [Penile cancer](https://onco.cc/cancers/penile/), [Rare cancers of childhood (NCI PDQ umbrella)](https://onco.cc/cancers/rare-childhood-cancers/), [Vaginal cancer](https://onco.cc/cancers/vaginal/), [Vaginal squamous cell carcinoma (HPV-associated)](https://onco.cc/cancers/vaginal-squamous-cell-carcinoma/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)
- journals: [Tumour virus research](https://onco.cc/journals/tumour-virus-research/)
- terms: [Cancer vaccines and oncolytic viruses](https://onco.cc/terms/vaccines-and-oncolytic-viruses/), [Enabling characteristic: tumour-promoting inflammation](https://onco.cc/terms/tumor-promoting-inflammation/), [Hepatitis B and C as cancer causes](https://onco.cc/terms/hbv-hcv/), [HPV status (HPV-positive / HPV-negative)](https://onco.cc/terms/hpv-status/), [HPV-positive (p16) head and neck cancer](https://onco.cc/terms/hpv-p16/), [Microenvironment and inflammation: tumours as wounds that do not heal](https://onco.cc/terms/microenvironment-inflammation-theory/), [Risk factor](https://onco.cc/terms/risk-factor/), [Squamous cell carcinoma](https://onco.cc/terms/squamous-cell-carcinoma/)
- trials: [A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males](https://onco.cc/trials/nct06465914/), [Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females](https://onco.cc/trials/nct04422366/), [IARC India HPV vaccine dose study (one, two or three doses)](https://onco.cc/trials/iarc-india-hpv-dose-study/), [KEN SHE (single-dose HPV vaccine)](https://onco.cc/trials/ken-she/), [PATRICIA](https://onco.cc/trials/patricia/), [RTOG 0129 (HPV analysis)](https://onco.cc/trials/rtog-0129/)
- drugs: [CERVAVAC (quadrivalent HPV vaccine, India)](https://onco.cc/drugs/cervavac/), [HB-200](https://onco.cc/drugs/hb-200/), [HPV bivalent vaccine (types 16 and 18)](https://onco.cc/drugs/hpv-bivalent-vaccine/), [HPV quadrivalent vaccine (types 6, 11, 16 and 18)](https://onco.cc/drugs/hpv-quadrivalent-vaccine/), [Nonavalent HPV vaccine](https://onco.cc/drugs/gardasil-9/)
- technologies: [Cancer interception vaccines](https://onco.cc/technologies/interception-vaccination/), [Colposcopes and digital cervical screening devices (DYSIS, EVA System, AVE)](https://onco.cc/technologies/colposcopes-digital-cervical-screening/), [Global oncology and access in low- and middle-income countries](https://onco.cc/technologies/global-oncology-access/), [HPV DNA testing and self-sampling](https://onco.cc/technologies/hpv-testing/), [Visual inspection with acetic acid (VIA) for cervical screening](https://onco.cc/technologies/via-cervical-screening/)
- ideas: [A delivery-science moonshot for prevention we already own](https://onco.cc/ideas/idea-fund-prevention-moonshot/), [A therapeutic vaccine to clear cervical precancer without surgery](https://onco.cc/ideas/idea-prev-therapeutic-hpv-vaccine-cin/), [Catch-up HPV vaccination for men to prevent throat cancer](https://onco.cc/ideas/idea-prev-hpv-male-catchup-oropharynx/), [Community-tailored HPV vaccine confidence campaigns with school-based delivery](https://onco.cc/ideas/idea-moon-hpv-vaccine-confidence/), [Eliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV](https://onco.cc/ideas/idea-moon-eliminate-infection-cancers/), [HPV self-testing with same-day treatment as the national cervical programme](https://onco.cc/ideas/idea-acc-hpv-self-sample-same-day-ablation/), [Offer HPV vaccination to women when they come for cervical screening or treatment](https://onco.cc/ideas/idea-prev-hpv-vaccinate-at-screening/), [Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries](https://onco.cc/ideas/idea-single-dose-hpv-self-sampling-elimination/), [Social impact bonds for cancer prevention, repaid from avoided treatment costs](https://onco.cc/ideas/idea-fund-social-impact-bonds-prevention/), [Switch every country to single-dose HPV vaccination and add catch-up to age 26](https://onco.cc/ideas/idea-prev-hpv-single-dose-switch-catchup/)
- institutions: [All India Institute of Medical Sciences, New Delhi](https://onco.cc/institutions/aiims-delhi/), [Cancer Institute (WIA), Adyar](https://onco.cc/institutions/cancer-institute-adyar/), [Catalan Institute of Oncology (ICO)](https://onco.cc/institutions/ico-catalonia/), [Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand](https://onco.cc/institutions/wits-charlotte-maxeke/), [Department of Biotechnology, Government of India](https://onco.cc/institutions/dbt-india/), [Dharmais National Cancer Center](https://onco.cc/institutions/dharmais-cancer-hospital/), [European Cancer Organisation](https://onco.cc/institutions/ecco/), [Gates Foundation](https://onco.cc/institutions/gates-foundation/), [German Cancer Research Center (DKFZ)](https://onco.cc/institutions/dkfz/), [Hospital de Amor (Barretos Cancer Hospital)](https://onco.cc/institutions/hospital-de-amor-barretos/), [ICMR-National Institute of Cancer Prevention and Research](https://onco.cc/institutions/icmr-nicpr/), [Institut National d'Oncologie, Rabat](https://onco.cc/institutions/institut-national-oncologie-rabat/), [Institut Pasteur](https://onco.cc/institutions/institut-pasteur/), [Institute of Oncology Ljubljana](https://onco.cc/institutions/onkoloski-institut-ljubljana/), [Instituto Nacional de Câncer (INCA)](https://onco.cc/institutions/inca-brazil/), [Instituto Nacional de Cancerología (Colombia)](https://onco.cc/institutions/inc-colombia/), [Instituto Nacional de Cancerología (Mexico)](https://onco.cc/institutions/incan-mexico/), [Instituto Nacional de Enfermedades Neoplásicas](https://onco.cc/institutions/inen-peru/), [Kaiser Permanente Division of Research](https://onco.cc/institutions/kaiser-permanente-research/), [Kenyatta National Hospital](https://onco.cc/institutions/kenyatta-national-hospital/), [Leiden University Medical Center](https://onco.cc/institutions/lumc-leiden/), [Markey Cancer Center, University of Kentucky](https://onco.cc/institutions/kentucky-markey/), [National Taiwan University Hospital](https://onco.cc/institutions/ntuh/), [NCI Center for Cancer Research (intramural programme)](https://onco.cc/institutions/nci-ccr/), [Ocean Road Cancer Institute](https://onco.cc/institutions/ocean-road-cancer-institute/), [Philippine General Hospital](https://onco.cc/institutions/philippine-general-hospital/), [Society of Gynecologic Oncology](https://onco.cc/institutions/sgo/), [Tongji Hospital, Huazhong University of Science and Technology](https://onco.cc/institutions/tongji-hospital-wuhan/), [Uganda Cancer Institute](https://onco.cc/institutions/uganda-cancer-institute/), [University of New Mexico Comprehensive Cancer Center](https://onco.cc/institutions/unm-cancer-center/), [World Health Organization Cancer Programme](https://onco.cc/institutions/who/)
- people: [André Ilbawi](https://onco.cc/people/ilbawi-andre/), [Bill Gates](https://onco.cc/people/bill-gates/), [Denise A. Galloway](https://onco.cc/people/denise-galloway/), [Douglas R. Lowy](https://onco.cc/people/douglas-lowy/), [Harald zur Hausen](https://onco.cc/people/harald-zur-hausen/), [Ian Frazer](https://onco.cc/people/ian-frazer/), [Jade Goody](https://onco.cc/people/jade-goody/), [Jian Zhou](https://onco.cc/people/jian-zhou/), [Mark Schiffman](https://onco.cc/people/mark-schiffman/), [Maura L. Gillison](https://onco.cc/people/maura-gillison/), [Mu-Sheng Zeng](https://onco.cc/people/zeng-mu-sheng/), [Nubia Muñoz](https://onco.cc/people/nubia-munoz/), [Partha Basu](https://onco.cc/people/basu-partha/), [Peter Sasieni](https://onco.cc/people/peter-sasieni/), [Rengaswamy Sankaranarayanan](https://onco.cc/people/sankaranarayanan-rengaswamy/)
- bottlenecks: [Misinformation and unproven therapies](https://onco.cc/bottlenecks/b-misinformation/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- pathways: [Basement membrane & tissue barriers](https://onco.cc/pathways/basement-membrane-tissue-barriers/), [Field cancerisation](https://onco.cc/pathways/field-cancerisation/), [Inflammation & NF-κB](https://onco.cc/pathways/inflammation-nfkb/), [Mutagenesis & mutational signatures](https://onco.cc/pathways/mutagenesis-signatures/), [Oncogenic viruses](https://onco.cc/pathways/oncogenic-viruses/)
- key papers: [Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis](https://onco.cc/key-papers/paper-patricia-paavonen-lancet-2009/), [England's HPV programme: cervical cancer down 87% in the first cohort vaccinated at 12-13](https://onco.cc/key-papers/paper-hpv-vaccine-england-lancet-2021/), [Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening](https://onco.cc/key-papers/paper-hpv-self-sampling-bmj-2018/), [Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17](https://onco.cc/key-papers/paper-hpv-vaccine-sweden-nejm-2020/), [Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India](https://onco.cc/key-papers/paper-basu-single-dose-hpv-lancet-oncol-2021/)
- companies: [Ananya Health](https://onco.cc/companies/ananya-health/), [Serum Institute of India](https://onco.cc/companies/serum-institute-of-india/)
- collections: [Gavi HPV vaccine support](https://onco.cc/collections/gavi-hpv-programme/), [NHS HPV vaccination programme](https://onco.cc/collections/nhs-hpv-vaccination/), [Vaccines for Children program (US)](https://onco.cc/collections/us-vaccines-for-children/)

---
JSON: https://onco.cc/api/v1/entities/hpv-vaccine.json